3B Blackbio DX Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,327.87Fairly Valued by 7.27%vs CMP ₹1,432.00

P/E (22.1) × ROE (19.8%) × BV (₹378.00) × DY (0.35%)

₹1,036.22Overvalued by 27.64%vs CMP ₹1,432.00

MoS: -38.2% (Negative)Confidence: 58/100 (Moderate)Models: 1 Under, 1 Fair, 7 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹1,451.43	22%	Fair (+1.4%)
Graham Number	Earnings	₹754.42	16%	Over (-47.3%)
Earnings Power	Earnings	₹323.40	11%	Over (-77.4%)
DCF	Cash Flow	₹1,088.59	13%	Over (-24%)
Net Asset Value	Assets	₹378.68	7%	Over (-73.6%)
EV/EBITDA	Enterprise	₹471.90	9%	Over (-67%)
Earnings Yield	Earnings	₹669.20	7%	Over (-53.3%)
ROCE Capital	Returns	₹3,220.80	9%	Under (+124.9%)
Revenue Multiple	Revenue	₹111.86	5%	Over (-92.2%)
Consensus (9 models)		₹1,036.22	100%	Overvalued

Key Drivers: Wide model spread (₹112–₹3,221) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 9.3%

*Investments are subject to market risks

Analysis summary

Data coverage: Price-data record updated 24 September 2026, 4:01 am +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.

Valuation in context

Operating performance

Revenue for Mar 2025 was ₹96.00 Cr, versus ₹74.00 Cr in Mar 2024 (29.7% year on year). Net profit for Mar 2025 was ₹48.00 Cr, versus ₹32.00 Cr in Mar 2024 (50.0% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.

Cash generation

For the same Mar 2025 period, operating cash flow was ₹43.00 Cr against net profit of ₹48.00 Cr. Cash flow covered 0.90 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.

Balance-sheet check

Reported borrowings were ₹3.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How to use the valuation and peer comparisons

The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.

The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.

Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.

Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.

Investment Snapshot

3B Blackbio DX Ltd scores 74/100 (Strong)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health96/100 · Strong

ROCE 25.5% ExcellentROE 19.8% ExcellentD/E 0.00 Low debtInterest Coverage 600.9x StrongProfitable 5/5 available years Reported history

Smart Money50/100 · Moderate

FII holding stable No changePromoter holding at 41.0% Stable

Earnings Quality65/100 · Strong

CFO/NP ratio: 0.85x Cash-backed earningsOPM stable around 48% SteadyWorking capital: 169 days Capital intensive

Quarterly Momentum68/100 · Strong

Revenue (4Q): +33% YoY AcceleratingProfit (4Q): +21% YoY PositiveOPM: 43.0% (down 16.0% YoY) Margin pressure

Industry Rank70/100 · Strong

P/E 22.1 vs industry 30.1 In-lineROCE 25.5% vs industry 15.5% Above peersROE 19.8% vs industry 15.4% Above peers3Y sales CAGR: 6% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing health ratios are excluded. Broad industry groups and financial-sector accounting can limit comparability.

Share Price and Basic Stock Data

Last Updated: September 24, 2026, 4:01 am

Market Cap	1,229 Cr.
Current Price	1,432
Intrinsic Value	₹1,036.22
High / Low	1,750/1,084
Stock P/E	22.1
Book Value	378
Dividend Yield	0.35 %
ROCE	25.5 %
ROE	19.8 %
Face Value	10.0
PEG Ratio	2.38

Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for 3B Blackbio DX Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
3B Blackbio DX Ltd	1,229 Cr.	1,432	1,750/1,084	22.1	378	0.35 %	25.5 %	19.8 %	10.0
Excel Industries Ltd	1,213 Cr.	963	1,265/800	17.0	1,355	1.43 %	6.17 %	4.62 %	5.00
Punjab Chemicals & Crop Protection Ltd	1,306 Cr.	1,065	1,534/876	19.5	345	0.28 %	18.6 %	16.6 %	10.0
Dharmaj Crop Guard Ltd	1,011 Cr.	299	335/211	16.8	133	0.00 %	16.8 %	13.3 %	10.0
Meghmani Organics Ltd	1,567 Cr.	61.6	86.4/36.4	24.4	60.7	0.00 %	6.71 %	1.90 %	1.00
Industry Average	8,982.90 Cr	968.36		30.11	378.31	0.61%	15.52%	15.36%	6.67

All Competitor Stocks of 3B Blackbio DX Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	15	18	14	19	18	23	19	29	25	22	22	34	50
Expenses	7	11	8	11	9	13	8	13	10	15	10	19	29
Operating Profit	7	7	6	8	9	10	11	16	15	8	12	15	22
OPM %	50%	41%	45%	41%	50%	43%	56%	55%	59%	35%	53%	43%	43%
Other Income	3	1	3	3	3	4	4	3	3	5	4	6	6
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	1	0
Profit before tax	10	8	9	10	11	14	14	19	18	13	16	20	27
Tax %	22%	38%	22%	26%	24%	36%	21%	23%	24%	36%	20%	23%	16%
Net Profit	8	5	7	8	9	9	11	15	13	8	13	15	22
EPS in Rs	8.96	7.72	9.71	10.46	10.16	10.33	12.97	17.07	15.61	9.79	14.67	17.14	25.32

Last Updated: March 3, 2026, 1:42 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:46 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	22	19	17	16	23	23	29	227	81	62	74	96	129
Expenses	21	18	16	14	18	16	20	77	44	33	41	46	73
Operating Profit	1	1	2	3	5	7	9	150	37	29	33	50	56
OPM %	6%	7%	9%	16%	23%	31%	32%	66%	46%	47%	44%	52%	44%
Other Income	0	0	0	0	0	1	2	3	7	7	13	15	20
Interest	1	1	1	1	1	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	1	1	1	1	1	1	1	2
Profit before tax	0	0	0	1	5	7	10	152	43	35	44	64	75
Tax %	14%	23%	23%	19%	24%	25%	23%	25%	26%	27%	28%	25%
Net Profit	0	0	0	1	3	5	8	114	32	26	32	48	58
EPS in Rs	0.59	0.36	0.51	1.76	5.35	8.18	10.24	151.66	42.89	34.55	37.40	55.57	66.92
Dividend Payout %	0%	0%	0%	17%	9%	6%	7%	6%	24%	8%	8%	7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	200.00%	66.67%	60.00%	1325.00%	-71.93%	-18.75%	23.08%	50.00%
Change in YoY Net Profit Growth (%)	0.00%	-133.33%	-6.67%	1265.00%	-1396.93%	53.18%	41.83%	26.92%

3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	18%
5 Years:	27%
3 Years:	6%
TTM:	25%

Compounded Profit Growth
10 Years:	70%
5 Years:	44%
3 Years:	14%
TTM:	34%

Stock Price CAGR
10 Years:	71%
5 Years:	32%
3 Years:	57%
1 Year:	-3%

Return on Equity
10 Years:	29%
5 Years:	30%
3 Years:	17%
Last Year:	19%

Last Updated: September 5, 2025, 1:56 pm

Balance Sheet

Last Updated: July 29, 2026, 3:30 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6	6	6	6	6	7	7	7	9	9	9	9
Reserves	4	4	5	12	16	25	125	146	185	214	260	316
Borrowings	8	8	9	6	6	4	2	3	2	1	0	3
Other Liabilities	7	6	6	6	8	9	59	37	19	24	27	51
Total Liabilities	25	24	26	30	36	45	194	192	214	248	296	378
Fixed Assets	4	3	3	4	4	4	5	7	8	7	7	28
CWIP	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	1	59	93	92	117	156	158
Other Assets	21	21	22	26	32	40	130	93	114	123	132	193
Total Assets	25	24	26	30	36	45	194	192	214	248	296	378

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	0	1	1	2	4	7	98	37	20	27	43	52
Cash from Investing Activity +	-0	-0	-0	-1	-1	-1	-70	-28	15	-20	-33	-24
Cash from Financing Activity +	-0	-1	-0	0	-1	1	-2	-15	-5	-4	-3	-1
Net Cash Flow	-0	0	0	1	2	7	26	-6	30	3	7	28
Free Cash Flow	0	1	0	1	3	6	96	35	18	26	42	27
CFO/OP	23%	69%	36%	52%	71%	101%	90%	129%	100%	115%	116%	121%

Free Cash Flow

Free cash flow reported in the stored cash-flow statement (₹ Cr)
Period	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Free Cash Flow	0.00	1.00	0.00	1.00	3.00	6.00	96.00	35.00	18.00	26.00	42.00	27.00

This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	213	262	283	321	259	290	252	56	136	200	179	138
Inventory Days	120	145	143	175						164	141	124
Days Payable	189	218	203	186						69	66	28
Cash Conversion Cycle	144	188	223	310	259	290	252	56	136	296	253	235
Working Capital Days	144	175	205	247	253	287	275	65	162	241	215	169
ROCE %	7%	7%	7%	13%	24%	28%	31%	162%	27%	19%	21%	26%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	38.43%	38.43%	41.29%	41.28%	41.28%	41.28%	41.28%	41.28%	41.28%	41.27%	40.94%	40.95%
FIIs	3.16%	3.38%	2.97%	3.28%	3.27%	2.68%	2.49%	2.70%	2.64%	2.57%	2.57%	2.50%
DIIs	0.82%	1.18%	1.89%	1.96%	1.96%	1.74%	1.60%	1.76%	1.82%	1.87%	1.98%	2.15%
Public	57.60%	56.99%	53.85%	53.48%	53.48%	54.29%	54.64%	54.28%	54.26%	54.27%	54.50%	54.40%
No. of Shareholders	10,513	10,088	9,753	9,399	9,586	10,166	10,345	10,619	10,709	10,507	10,616	11,049

Shareholding Pattern Chart

No. of Shareholders

3B Blackbio DX Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	55.57	37.40	34.55	43.40	151.66
Diluted EPS (Rs.)	55.57	37.40	34.55	43.40	151.66
Cash EPS (Rs.)	56.93	38.70	35.77	43.88	152.82
Book Value[Excl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Book Value[Incl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Revenue From Operations / Share (Rs.)	112.59	86.51	82.54	107.65	302.66
PBDIT / Share (Rs.)	76.08	53.12	48.55	58.73	204.07
PBIT / Share (Rs.)	74.82	51.88	47.40	57.84	203.25
PBT / Share (Rs.)	74.69	51.74	47.13	57.69	202.94
Net Profit / Share (Rs.)	55.66	37.46	34.62	42.98	152.00
NP After MI And SOA / Share (Rs.)	55.66	37.46	34.62	42.98	152.00
PBDIT Margin (%)	67.57	61.40	58.81	54.56	67.42
PBIT Margin (%)	66.45	59.97	57.42	53.72	67.15
PBT Margin (%)	66.34	59.80	57.10	53.59	67.05
Net Profit Margin (%)	49.43	43.30	41.94	39.92	50.21
NP After MI And SOA Margin (%)	49.43	43.30	41.94	39.92	50.21
Return on Networth / Equity (%)	17.76	14.39	15.14	21.04	86.23
Return on Capital Employeed (%)	23.13	19.28	17.76	24.73	101.13
Return On Assets (%)	16.12	12.93	12.11	16.76	58.83
Long Term Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Total Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Asset Turnover Ratio (%)	0.35	0.32	0.30	0.13	0.38
Current Ratio (X)	7.11	7.04	8.05	4.82	2.76
Quick Ratio (X)	6.64	6.56	7.49	4.38	2.64
Inventory Turnover Ratio (X)	11.24	2.41	2.33	2.66	2.68
Interest Coverage Ratio (X)	600.85	365.87	183.32	413.58	669.53
Interest Coverage Ratio (Post Tax) (X)	440.55	259.05	131.73	303.65	499.68
Enterprise Value (Cr.)	1319.35	600.55	278.94	248.35	196.43
EV / Net Operating Revenue (X)	13.68	8.10	4.51	3.08	0.86
EV / EBITDA (X)	20.24	13.19	7.67	5.64	1.28
MarketCap / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
Price / BV (X)	5.16	2.96	1.82	1.67	1.62
Price / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
EarningsYield	0.03	0.04	0.08	0.12	0.53

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Frequently asked questions

What is the intrinsic value of 3B Blackbio DX Ltd and is it undervalued?

3B Blackbio DX Ltd: the stored intrinsic value estimate is ₹1,036.22, compared with a stored share price of ₹1,432.00. The model value is 27.6% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.

What share price and 52-week range are shown for 3B Blackbio DX Ltd?

The stored share price is ₹1,432.00. Price-data record updated: 24 September 2026, 4:01 am +05:30. This is not a live quote. The stored 52-week high / low is 1,750/1,084; this is a rolling range, not a financial-year range.

How have 3B Blackbio DX Ltd's revenue and profit changed?

Does 3B Blackbio DX Ltd's profit convert into cash?

What should I check in 3B Blackbio DX Ltd's balance sheet?

Reported borrowings were ₹3.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How should I compare 3B Blackbio DX Ltd's P/E with other stocks?

The stored P/E is 22.10. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.

What could change 3B Blackbio DX Ltd's intrinsic value estimate?

Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.